Macular degeneration - cystoid
Methodology & AI Transparency ⓘ
Macular degeneration - cystoid Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as H35.359, Macular degeneration - cystoid falls under Eyes & Vision management, where AREDS2 macular nutrition [Macular degeneration - cystoid H35.359] establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Diagnostic registry H35.359: Macular degeneration - cystoid is managed within Eyes & Vision.
- 3 Typical cash cost range: Workup highlights for Macular degeneration - cystoid (H35.359): AREDS2 macular nutrition [Macular degeneration - cystoid H35.359].
- 4 Top reported side effects / signs: Follow-up benchmark in Macular degeneration - cystoid: maintaining Best-Corrected Visual Acuity in Macular degeneration - cystoid (H35.359: & OCT) within Intact retinal nerve fiber & macula (H35.359).
Ask our AI Specialists anything about Macular degeneration - cystoid
What Is Macular degeneration - cystoid?
Designated in federal medical registries as H35.359, Macular degeneration - cystoid falls under Eyes & Vision management, where AREDS2 macular nutrition [Macular degeneration - cystoid H35.359] establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Macular degeneration - cystoid (code H35.359) is retinal pigment epithelium in Macular degeneration - cystoid (H35.359: oxidative drusen accumulation), which Eye Health, Glaucoma & Vision Disorders clinicians address while surveilling Best-Corrected Visual Acuity in Macular degeneration - cystoid (H35.359: & OCT) (Intact retinal nerve fiber & macula (H35.359)).
Common Symptoms & Clinical Signs
- • Presentation of Macular degeneration - cystoid (H35.359): gritty burning, foreign-body in Macular degeneration - cystoid (H35.359: sensation, reflex tearing,)
- • Secondary Macular degeneration - cystoid clinical sign: loss of peripheral in Macular degeneration - cystoid (H35.359: side vision)
- • Symptom flares in Macular degeneration - cystoid correlating with Best-Corrected Visual Acuity in Macular degeneration - cystoid (H35.359: & OCT) deviation outside Intact retinal nerve fiber & macula (H35.359)
- • Functional eyes & vision impact requiring AREDS2 macular nutrition [Macular degeneration - cystoid H35.359] evaluation (H35.359)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Macular degeneration - cystoid Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | H35.359 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Eye Health, Glaucoma & Vision Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Best-Corrected Visual Acuity in Macular degeneration - cystoid (H35.359: & OCT) | Intact retinal nerve fiber & macula (H35.359) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HbA1c & Systemic in Macular degeneration - cystoid (H35.359: Blood Pressure) | Microvascular retinal protection (H35.359) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Intraocular Pressure (IOP) [Macular degeneration - cystoid H35.359] | 10 – 21 mmHg (individualized optic target) (H35.359) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Macular degeneration - cystoid
Treatment selection for Macular degeneration - cystoid depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Macular degeneration - cystoid)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Dietary Nutrient Intake and Progression to Late Age-Related Macular Degeneration: What a 4,504-Participant Study Found Higher dietary intake of multiple nutrients, including minerals, vitamins, and carotenoids, is associated with decreased risk of progression to late AMD. Ophthalmology • 2021-03-15 • Phase III Randomized Trial | N = 4,504 | 90/100 | PMID 32858063 ↗ |
| New Insights on EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE: What a 1,752-Participant Study Found More stable CST was associated with better visual outcomes at the end of treatment suggesting that CST variability may provide a more reliable prognostic marker of visual outcomes than the presence of fluid alone, with the... Retina (Philadelphia, Pa.) • 2022-03-01 • Phase III Randomized Trial | N = 1,752 | 90/100 | PMID 34923515 ↗ |
| New Insights on Association between screening duration and treatment outcomes in the clinical: What a 1,152-Participant Study Found Linear regression coefficients for screening duration were not statistically significant for BCVA or CST at week 8 (BCVA: B = - 0.058, P = 0.242; CST: B = - 0.050, P = 0.908) or at week 48 (BCVA: B = - 0.015, P = 0.843; CST: B... Scientific reports • 2026-04-02 • Phase III Randomized Trial | N = 1,152 | 90/100 | PMID 41927600 ↗ |
| New Insights on Subretinal Fluid Resolution and Visual Acuity in Patients with Neovascular: What a 1,097-Participant Study Found A greater proportion of ranibizumab-treated eyes with nAMD gained/maintained visual acuity at SRF resolution. Ophthalmology. Retina • 2022-11-15 • Phase III Randomized Trial | N = 1,097 | 90/100 | PMID 35654363 ↗ |
| Can This Approach Help? Inside the Latest Research on Resolution of outer retinal abnormalities in eyes with vitreomacular traction ELM disruption, EZ disruption and/or SRF are present in a significant percentage of eyes with VMT without MH. The British journal of ophthalmology • 2023-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35288439 ↗ |
Macular degeneration - cystoid Patient Community & “People Like Me” Threads
Filter Macular degeneration - cystoid community threads and patient logs by age, biological sex, dosage, and treatment duration.